Don J. Diamond, Ph.D. COH04S1, a City of Hope-developed COVID-19 investigational vaccine, stimulated broad-spectrum protective immunity against SARS-CoV-2 variants in new preclinical research due to its inclusion of both...

CONTACT Letisia Marquez 626-476-7593lemarquez@coh.org   Chimeric antigen receptor (CAR)-NK cell therapy to treat the virus is one of more than two dozen COVID-19 research projects underway   DUARTE, Calif...

As City of Hope’s research to find better treatments for cancer and diabetes continues during the COVID-19 pandemic, the institution’s renowned physician-scientists are also using their expertise to attack the deadly...

City of Hope is now enrolling patients in a Phase 2 clinical trial of its COH04S1 vaccine, which is the first to study the safety and effectiveness of an investigational...

“It’s not HIV that kills you, it’s the co-infections that do,” said Javier Gordon Ogembo, Ph.D., associate professor in the Department of Immuno-Oncology at City of Hope.   Among the deadliest...

CONTACT Letisia Marquez 626-476-7593lemarquez@coh.org   DUARTE, Calif. — ProBioGen AG has announced a commercial product license agreement with City of Hope®, a world-renowned independent research and treatment center for...

CONTACT Letisia Marquez 626-476-7593lemarquez@coh.org   The investigational vaccine is the first-of-its-kind for type 1 diabetes to be tested in the United States and showed positive results in an early...

A COVID-19 investigational vaccine developed by City of Hope scientists and now licensed to GeoVax Labs Inc. produced a robust neutralizing antibody and T cell (an immune cell) response against...

CONTACT Letisia Marquez 626-476-7593lemarquez@coh.org   •    The vaccine strategy used to generate this candidate has a record of safety and efficacy, rapid immune response and lasting protection   •  ...

Saul Priceman, Ph.D. At the moment, there is no vaccine and no medication that has been proven to target COVID-19. All we have right now is the body’s own frontline...